| 20.51 -0.75 (-3.53%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.83 | 1-year : | 31.34 |
| Resists | First : | 22.97 | Second : | 26.83 |
| Pivot price | 19.86  |
|||
| Supports | First : | 18.66 | Second : | 16 |
| MAs | MA(5) : | 19.98  |
MA(20) : | 19.3 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 47.2 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 22.97 | Low : | 14.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SPTX ] has closed below upper band by 39.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 21.48 - 21.6 | 21.6 - 21.7 |
| Low: | 19.11 - 19.27 | 19.27 - 19.4 |
| Close: | 20.27 - 20.51 | 20.51 - 20.71 |
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Mon, 08 Jun 2026
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Mon, 08 Jun 2026
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Mon, 11 May 2026
General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% Stake - TradingView
Mon, 04 May 2026
SPTX | Seaport Therapeutics, Inc. Common Stock Data, Price & News - Quiver Quantitative
Sat, 02 May 2026
Seaport Therapeutics (SPTX) Stock Price, News & Analysis - MarketBeat
Fri, 01 May 2026
Seaport, Hemab price upsized IPOs (SPTX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 35 (%) |
| Held by Institutions | 29.7 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 1,460 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -12.51 |
| PEG Ratio | 0 |
| Price to Book value | -1.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|